Logo

PARP inhibitors

MNM Bioscience Wins $800K Eurostars Grant to Stratify Ovarian Cancer Patients

The bioinformatics startup will work with Macrogen Europe to develop an AI-based tool for analyzing WGS data to identify patients who should receive PARP inhibitors.

Burning Rock, Impact Therapeutics Ink Testing Deal for ATR Inhibitor

The company will test samples to support Impact's Phase I/II trial combining the investigational drug IMP9064 with the PARP inhibitor senaparib.

Genetron Health, Impact Therapeutics Partner for Anti-Cancer Drug, CDx Development

The companies will cooperate in drug target discovery and, potentially, companion diagnostic development for novel synthetic lethal inhibitors.

Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib

The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.

Prostate Cancer Genomics Study IDs PARP Inhibitors as Potentially Beneficial to Black Men

Some genes were more frequently mutated in prostate cancers from Black men, but the researchers said that social inequities also lead to poorer health outcomes.

Aug 7, 2019

Personalis to Provide Immunogenomic Profiling for University of New Mexico Ovarian Cancer Study

Apr 18, 2019

Harvard Team Advancing Algorithmic Signature to Improve PARP Inhibitor Patient Selection
Premium

Dec 19, 2018

FDA Approves Myriad Genetics' BRACAnalysis CDx With Lynparza in Earlier Ovarian Cancer Setting

Oct 16, 2018

FDA Approves Myriad Genetics BRCA CDx With Pfizer's Metastatic Breast Cancer Drug

Oct 10, 2018

Myriad Upgraded to Overweight by Piper Jaffray; Signs Lab Service Deal with Pfizer

Sep 28, 2018

BRCA1 Methylation Level May Predict Which Ovarian Cancer Patients Respond to PARP Inhibitors

Jul 16, 2018

PARP Inhibitors May Benefit Patients With Rare Hereditary Cancer Syndromes

May 31, 2018

PanDrugs System Aims to Advance Precision Cancer Care by Matching Treatments to Mutations
Premium

May 11, 2018

PARP Inhibitor Resistance Gene Identified Using CRISPR Screen

Dec 8, 2017

Pfizer PARP Inhibitor Delays Progression Over Chemotherapy in BRCA-Mutated Advanced Breast Cancer
Premium

Jul 11, 2017

After Securing CE-IVD for Debut Hereditary Cancer Dx, Korea's NGeneBio Readies NGS Tests for Launch
Premium

Mar 27, 2017

FDA Approves Myriad Genetics' BRACAnalysis as Complementary Dx for New PARP Inhibitor

Feb 1, 2017

Clovis, Strata Partner to Identify Prostate Cancer Best Responders to PARP Inhibitor

Dec 20, 2016

Foundation Medicine's Regulatory Win for NGS CDx Sets Precedent; Adoption Challenge Remains
Premium

Dec 19, 2016

Foundation BRCA CDx is First NGS Companion Test to Get FDA Nod

Nov 2, 2016

Myriad Moving Ahead With PMA Filing for MyChoice HRD as Companion Test for Niraparib
Premium

Jul 6, 2016

Ovarian Cancer Study Provides Support for Myriad's HRD Test as CDx for Tesaro's Niraparib
Premium

Jun 6, 2016

AstraZeneca Outlines Precision Medicine Strategy for DNA Damage Response Portfolio
Premium

Mar 1, 2016

Multiplicom Receives CE-IVD Mark for Ovarian Cancer CDx Test

Feb 23, 2016

AbbVie to Use Myriad CDx to Support PARP Inhibitor Development

Breaking News
The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.